Serology of abnormal fracture healing: the role of PIIINP, PICP, and BsALP.

J Orthop Trauma

Department of Orthopaedics, South Manchester University Hospitals NHS Trust, Manchester, United Kingdom.

Published: January 2000

Objective: To determine whether poorly healing tibial shaft fractures exhibit a serological response of bone-specific alkaline phosphatase (BsALP), collagen I carboxy-terminal propeptide (PICP), collagen III amino-terminal propeptide (PIIINP), and collagen I carboxy-terminal telopeptide (ICTP) different from that of normally healing fractures.

Design: Prospective.

Participants: Twenty consecutive patients with isolated tibial shaft fractures with or without fracture of the fibula.

Main Outcome Measurements: Assays of BsALP, PICP, PIIINP, and ICTP were performed with serum samples taken at standard intervals from twenty-four hours to twenty weeks after fracture. Fracture healing was assessed at five, ten, fourteen, and twenty weeks for clinical and radiological evidence of union.

Results: Seventeen fractures united within the twenty-week study period. The three fractures exhibiting delayed union demonstrated significantly lower PICP levels and marginally lower BsALP levels at twenty weeks. PIIINP levels were significantly higher in these three fractures at ten weeks. There was no difference in ICTP between the seventeen united and the three ununited fractures.

Conclusions: This study identified three serological features of a poor healing response in tibial shaft fractures. First, matrix collagen I and III production in the first ten weeks of healing was adequate, with evidence of significantly increased production of type III collagen. Second, there was no serological evidence of a deficient osteoblast response, as indicated by normal levels of BsALP and PICP, during this early period. Third, evidence of a deficient osteoblast response appeared only at twenty weeks after injury.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00005131-200001000-00010DOI Listing

Publication Analysis

Top Keywords

twenty weeks
16
tibial shaft
12
shaft fractures
12
fracture healing
8
collagen carboxy-terminal
8
collagen iii
8
bsalp picp
8
three fractures
8
ten weeks
8
evidence deficient
8

Similar Publications

To examine the effects of self-paced combined high-intensity interval training and resistance training (HIIT-RT) on oxidative stress, inflammation lipid profile and body composition in people with multiple sclerosis (PwMS). Twenty-three PwMS were randomly assigned to either a control group (CG, n = 12) or a training group (TG, n = 11). The TG performed a 12-week self-paced HIIT-RT (3 times/week).

View Article and Find Full Text PDF

Purpose: To analyze Tocilizumab (TCZ, an interleukin 6 inhibitor) as a second-line treatment for thyroid-associated ophthalmopathy (TAO).

Methods: In this retrospective observational study, the charts of patients with moderately severe to severe TAO who received intravenous Tocilizumab as a second-line treatment 2020-2023 were reviewed.

Results: Twenty-three patients were enrolled in the study.

View Article and Find Full Text PDF

Objectives: To study the clinical effect of the L-shape technique combined with concentrated growth factor on the horizontal bone defects of maxillary anterior teeth.

Methods: Twenty-five implants from 25 patients who underwent single maxillary anterior tooth implantation with simultaneous bone grafting were selected as the study subjects. Based on the bone grafting techniques, the patients were divided into a test group (L-shaped technique with guided bone regeneration combined with concentrated growth factor, 11 cases) and a control group (traditional guided bone regeneration combined with concentrated growth factor, 14 cases).

View Article and Find Full Text PDF

Objectives: The feasibility of corticosteroid withdrawal (CW) for Takayasu arteritis (TAK) remains uncertain. Two autoantibodies (Abs) are identified against endothelial protein C receptor (EPCR) and scavenger receptor class B type 1 (SR-BI) in TAK, determining its three subgroups. This study aimed to evaluate CW using tocilizumab (TCZ) and its association with the Ab profile.

View Article and Find Full Text PDF

Background: China has a large number of myasthenia gravis (MG) patients, creating an urgent need for rapid and tolerable treatment options. As the first-approved Fc receptor antagonist, efgartigimod has bright prospects for treating MG. However, real-world evidence on its application within the Chinese MG population are limited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!